Navigation Links
Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
Date:8/21/2008

me to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.

The study is enrolling patients with all HCC histologies. Patients will be randomized to receive 400 mg of Nexavar twice daily or matching placebo for up to four years. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region, including Japan. For information about enrolling in the study, please visit http://www.clinicaltrials.gov.

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.(1,2)

Currently there are no adjuvant treatments with proven benefit in HCC and half of the patients who have undergone surgical resection or local ablation will see their tumors return within three years and 70 percent will see their tumors return within five years.(3)

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in m
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCarePharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
2. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
8. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
9. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... Thirteen Abstracts Will Be Featured at Annual Kidney Care ... leading provider of kidney care services for those diagnosed ... with DaVita Clinical Research(R), today announced that company representatives ... 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 ...
... Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has been selected to present the ... to Assess the Safety,Pharmacokinetics (PK) and Pharmacodynamics ... Type 2 Diabetes (T2DM)" at the upcoming ...
Cached Medicine Technology:DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) 2
(Date:7/30/2014)... The household income of its residents is the most ... rates of avoidable hospital visits conditions that could be ... settings if treated at an early stage, according to a ... Policy (CSHP). , An analysis of hospital billing records ... in New Jersey found that as an area,s per capita ...
(Date:7/30/2014)... The Hearing Aid Clinics industry is ... 2014. Following a multiyear drop during the recession, the ... expansion of private healthcare coverage and, ultimately, the improving ... Aid Clinics industry revenue will increase at an ... five years to 2014. , According to IBISWorld Industry ...
(Date:7/30/2014)... Francisco, California (PRWEB) July 30, 2014 ... reach USD 5,440.5 million by 2020, growing at an ... to a new study by Grand View Research, Inc. ... prevalence of deafness is expected to serve this market ... usage rates of 100% digital hearing aid technology and ...
(Date:7/30/2014)... genetic mutation linked to obesity respond differently to pictures ... do not have the genetic mutation, according to a ... of Clinical Endocrinology & Metabolism ( JCEM ). ... typically results from a combination of eating too much, ... consumption of appetizing foods that are high in calories ...
(Date:7/30/2014)... died of a caffeine overdose in May highlighted the ... To help prevent serious health problems that can arise ... toward a rapid, at-home test to detect even low ... breast milk. Their report appears in ACS, Journal ... and colleagues note that caffeine,s popularity as a "pick-me-up" ...
Breaking Medicine News(10 mins):Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2
... NASHVILLE, Tenn., Nov. 4 Healthcare Realty,Trust Incorporated ... stock cash,dividend for the quarter ended September 30, ... share, is payable on December 3, 2008 to ... Realty Trust is a real estate investment trust ...
... Covisint to Link Hospitals in Michigan,s "Thumb" ... and Improving Healthcare Delivery, Costs, DETROIT, ... ) today announced that its Covisint subsidiary ... now called,Michigan Thumb Health Information System (THIS). ...
... to reduce acute attacks by lowering serum urate levels, which ... high serum urate levels have been shown to lower the ... the safety and efficacy of febuxostat, a new drug being ... Europe, and a commonly used drug that has been around ...
... team led by Mitchell Lazar, MD, PhD, Director of ... University of Pennsylvania School of Medicine, has used state-of-the-art ... molecular "master regulator" of fat-cell biology is nestled in ... appear online this week in Genes & Development ...
... of animal free and defined cell culture media components will feature ... ... Fort Collins, CO (PRWEB) November 4, 2008 -- InVitria,s ... albumins in cell culture, will be featured at the 2nd International ...
... BeaconEquity.com announces the,availability of Trade Alerts on stocks ... the daily trading notes for free by visiting:, http://www.BeaconEquity.com/m ... (NYSE: WMT ),Advanced Medical Optics Inc. (NYSE: ... (NYSE: EXP ), QLogic Corp. (Nasdaq: QLGC ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Dividend 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 2Health News:Compuware Covisint to Securely Connect, Integrate Michigan's Thumb Health Information System 3Health News:Studies examine treatment for gout and the condition's protective effects 2Health News:Studies examine treatment for gout and the condition's protective effects 3Health News:Penn scientists map molecular regulation of fat-cell genetics 2Health News:InVitria to Present at WilBio's International Cell Engineering Meeting 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 3
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
... with Vacuum Controller V-800 Efficiently controls vacuum ... on and off as needed to maintain preset vacuum ... PTFE membrane vacuum pump designed to handle most vacuum ... with up to two rotary evaporators Laboratory ...
... BchiVac V-500 and water-cooled secondary condenser to ... a powerful PTFE membrane vacuum pump designed ... Ideally suited for use with ... Laboratory vacuum source for instruments including vacuum ...
Medicine Products: